Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections
Sadaf Marashi Pour, Ian Woolley, Peter Canavan, John Chuah, Darren B Russell, Matthew Law, Kathy Petoumenos
Sexual Health | CSIRO PUBLISHING | Published : 2011
Awarded by USA National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID)
IW has received consultancy fees from BMS and Gilead, and research funds from Gilead and Merck Sharp & Dohme. The other writing committee members have no conflicts of interest to declare.The Australian HIV Observational Database is funded as part of the Asia-Pacific HIV Observational Database, a program of The Foundation for AIDS Research (amfAR) and is supported in part by a grant from the USA National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) (Grant No. U01-AI069907) and by unconditional grants from Merck, Sharp & Dohme; Gilead; Bristol-Myers Squibb; Boehringer Ingelheim; Roche; Pfizer; GlaxoSmithKline and Janssen-Cilag. The National Centre in HIV Epidemiology and Clinical Research is funded by The Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales.